Matthew Kirkpatrick is a Rheumatology/Immunology physician. OpenAlex indexes 130 publications with 4,764 citations (h-index 35); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
931 Highland Blvd Ste 3260
Bozeman, MT 597156907
Telephone
406-414-2410Provider last certified this registry record 9 Apr 2025.
Clinical trials
- Mindfulness Training for Smoking Cessation
Sponsor: University of Southern California
- Couples Dynamics and Smoking Cessation
Sponsor: University of Southern California
- Mindfulness Training Plus Oxytocin Effects on Smoking Behavior
Sponsor: University of Southern California
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20252 payments
- PFIZER INC.Program year20251 payment
- ABBVIE INC.Program year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.7%Folate Analog Metabolic Inhibitor16.7%Methotrexate100%Part D≥39 patientsTNF inhibitor4.4%Humira(Cf) Pen69%Humira(Cf)31%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
25.8%Corticosteroid21.8%Prednisone100%Part D≥68 patientsAminosalicylate2.4%Sulfasalazine Dr100%Part D<11 patients+ 1 more class in this area
Nervous system
17.4%Gabapentinoids15%Gabapentin82%Pregabalin18%Part D<11 patientsNonsteroidal Anti-inflammatory Drug2.4%Meloxicam100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”